Search: (WFRF:(Tellier G)) >
Clinical and bacter...
Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia.
-
Carbon, C (author)
-
van Rensburg, D (author)
-
- Hagberg, Lars, 1951 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine
-
show more...
-
Fogarty, C (author)
-
Tellier, G (author)
-
Rangaraju, M (author)
-
Nusrat, R (author)
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2006
- 2006
- English.
-
In: Respiratory medicine. - : Elsevier BV. - 0954-6111. ; 100:4, s. 577-85
- Related links:
-
http://www.resmedjou...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- This retrospective analysis was performed to determine the clinical and bacteriologic efficacy of the ketolide antibacterial telithromycin in patients with community-acquired pneumonia (CAP) with pneumococcal bacteremia. Patients 13 years old with radiologically confirmed CAP and a positive blood culture for Streptococcus pneumoniae at screening were analyzed from eight multicenter Phase III/IV clinical trials. In four open-label, non-comparative studies, patients received telithromycin 800 mg once daily for 7-10 days. In four randomized, controlled, double-blind, comparative studies, patients received telithromycin 800 mg once daily for 5-10 days or a comparator antimicrobial (amoxicillin 1000 mg three times daily, clarithromycin 500 mg twice daily, or trovafloxacin 200 mg once daily) for 7-10 days. In total, 118 patients (telithromycin, 94/1061 [8.9%]; comparator, 24/244 [9.8%]) had documented pneumococcal bacteremia. Those who were treated with telithromycin achieved a clinical cure rate of 90.2% (74/82, per-protocol population); S. pneumoniae was eradicated in 77/82 (93.9%) bacteremic patients who received telithromycin and 15/19 (78.9%) comparator-treated patients. Clinical cure was also observed among telithromycin-treated bacteremic patients who were infected with penicillin- or erythromycin-resistant strains of S. pneumoniae (5/7 and 8/10, respectively). In conclusion, telithromycin achieves high clinical and bacteriologic cure rates in CAP patients with pneumococcal bacteremia.
Keyword
- Adolescent
- Adult
- Aged
- Anti-Bacterial Agents
- administration & dosage
- therapeutic use
- Clinical Trials
- Phase IV
- Community-Acquired Infections
- drug therapy
- microbiology
- Female
- Humans
- Ketolides
- administration & dosage
- therapeutic use
- Male
- Meta-Analysis
- Middle Aged
- Multicenter Studies
- Pneumonia
- Bacterial
- drug therapy
- microbiology
- Randomized Controlled Trials
- Retrospective Studies
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database